Paratek Pharmaceuticals Inc

Paratek Pharmaceuticals — Transcept Pharmaceuticals — Investor Presentation (September 2013)

27 slides from Paratek Pharmaceuticals's investor presentation, Sep 25, 2013

  1. Slide 1: Specialty pharmaceutical company focused on neuroscience

    September 2013 A specialty pharmaceutical company focused on the development and commercialization of proprietary products to address important therapeutic needs in the field of neuroscience NASDAQ:TSPT

  2. Slide 2: Forward-looking statements

    Forward-looking statements This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding our strategy, future operations, future financial position, future re

  3. Slide 3: Neuroscience focused specialty pharmaceutical company

    Transcept Pharmaceuticals: Neuroscience focused specialty pharmaceutical company 3  First and only product approved for middle of the night insomnia  US primary care marketing agreement: Purdue Pharma INTERMEZZO® for MOTN insomnia  ~$78MM in cash as of 6/30/13; no debt Strong balance sheet  Succ

  4. Slide 4: Proprietary nasal powder drug delivery technology

    Proprietary nasal powder drug delivery technology

  5. Slide 5: Nasal drug delivery: significant market opportunity

    Nasal drug delivery Significant market opportunity  U.S. nasal Rx drug delivery market estimated > $3B in 2013  Nasal cavity: potentially efficient drug delivery path – Nasal mucosa is permeable and leads to a significant vascular capillary bed – Safety advantages vs. e.g., pulmonary delivery  Ho

  6. Slide 6: Shin Nippon Biomedical Laboratories: Optimizing nasal drug delivery

    Shin Nippon Biomedical Laboratories: Optimizing nasal drug delivery  Major Contract Research Organization with over 2,000 employees across the United States, Asia and Europe  Established 1957  Provides comprehensive range of non-clinical and clinical development services to biopharmaceutical comp

  7. Slide 7: SNBL nasal powder drug delivery system

    SNBL nasal powder drug delivery system: Proprietary muco-adhesive carrier + novel delivery device 7  SNBL carrier technology – Dry powder formulation – Effective muco-adhesive carrier – Consists of generally recognized as safe “GRAS” components – Excellent safety profile demonstrated – Portfolio of

  8. Slide 8: SNBL nasal powder: superior bioavailability in primates

    SNBL nasal powder drug delivery system: superior bioavailability to traditional nasal sprays in primates 8 Zolmitriptan in primates (Migraine) Calcitonin in primates (Osteoporosis) 0 200 400 600 800 1000 1200 0 120 240 360 480 P las m a c o n c e n tra ti o n (n g /m L ) Zomig® Nasal Spray (5mg/anim

  9. Slide 9: Human studies confirm primate PK results

    0 1 2 3 4 5 6 7 8 9 0.0 0.5 1.0 1.5 2.0 2.5 3.0 3.5 4.0 4.5 5.0 5.5 6.0 Zo lmi tri p ta n Co n ce n tr at io n ( n g /m L) Time (h) TRZ 0.75 mg TRZ 1.5 mg TRZ 3.0 mg Zomig NS 5 mg 9 SNBL nasal powder delivery system: Human studies confirm primate PK results SNBL zolmitriptan powder 0.75 mg SNBL nasa

  10. Slide 10: TO-2070: rapid and sustained relief of acute migraine

    TO-2070: designed for rapid and sustained relief of acute migraine

  11. Slide 11: Migraine: large market with significant unmet needs

    Migraine: large market with significant unmet needs 11  US and Western Europe 1-year prevalence:11% overall1 – According to a WHO survey, a day with severe migraine is as disabling as a day with quadriplegia2  In US each year: ~30MM cases; $2.6B Rx product sales3  ~80% of migraine Rx patients wou

  12. Slide 12: DHE: a trusted treatment for migraine

    DHE: a trusted treatment for migraine Need for improved delivery systems 12  DHE has long been recognized as an effective treatment for migraine – Approved for use in the United States since 1946 – Frequently used by migraine specialists in triptan failures  Poor oral bioavailability – Generally a

  13. Slide 13: TO-2070: a better way to deliver DHE for migraine

    TO-2070: a better way to deliver DHE for migraine  Rapidly absorbed – Bioavailability expected to be comparable to IM and pulmonary (LevadexTM) – Superior to conventional nasal sprays  Sustained efficacy – DHE is associated with lower recurrence rates versus triptans1 – Sustained high bioavailabil

  14. Slide 14: TO-2070 rapid and consistent absorption in primates

    0.01 0.1 1 10 100 0 1 2 3 4 5 6 7 8 P la sm a c on ce nt ra tion (n g/ m L) Time (hrs) IV (0.1 mg) TO-2070 (0.1mg) TO-2070 shows rapid and consistent absorption in primates (n=6) (Median Tmax = 17.5 minutes) 14

  15. Slide 15: TO-2070 vs Migranal liquid nasal spray in primates

    0 1 2 3 4 5 6 0 1 2 3 4 P la s m a c o n c e n tr a tion +/- S E (n g /m L ) Time (hrs) TO-2070 (0.5mg) Migranal (0.5mg) TO-2070 vs Migranal® liquid nasal spray in primates: Earlier Cmax with twice the drug exposure in first 30 minutes 15 Ratio 2:1 0-30 minute AUC data 0-4 hour plasma profile primat

  16. Slide 16: TO-2070 vs DHE intramuscular injection in primates

    0.1 1 10 0 1 2 3 Pla sm a c on ce nt ra tion (n g/ m L) Time (hrs) IM (0.1mg) TO-2070 (0.5mg) TO-2070 vs DHE intramuscular injection (IM) in primates: Comparable PK profiles 0 to 3 hours 16 TO-2070 (primate data, n=6) TO-2070

  17. Slide 17: Allergan's Levadex (under FDA review)

    Allergan’s Levadex (under FDA review)  Developed by MAP Pharmaceuticals; acquired by Allergan for ~$1.0 B (2013)  Pulmonary inhalation DHE product  Approval expected mid-2014  Anticipated pricing >$75 - 100 per dose  Allergan and analysts forecast $500MM in peak US sales 17 Potential drawbacks

  18. Slide 18: TO-2070 initial development program

    TO-2070 initial development program  License agreement signed September, 2013  IND target date: 1H 2014  Human PK data expected: 2H 2014  NDA strategy to be finalized following FDA meeting  Potential for 505(b)(2) regulatory pathway based on well- characterized nature of DHE 18

  19. Slide 19: Initial Key Opinion Leader feedback on DHE nasal powder

    Initial Key Opinion Leader (KOL) feedback regarding DHE nasal powder for acute migraine

  20. Slide 20: Summary of Key Opinion Leader feedback

    Summary of Key Opinion Leader (KOL) feedback  Migraine KOLs believe that DHE is an excellent treatment for many migraine patients, but better dosage forms are needed  Experts believe that the SNBL intranasal delivery technology applied to DHE offers promise for improving the management of acute mi

  21. Slide 21: INTERMEZZO

    INTERMEZZO® Transcept

  22. Slide 22: Intermezzo: first and only sleep aid approved for middle-of-the-night dosing

    Intermezzo: the first and only prescription sleep aid approved for middle-of-the-night dosing 22

  23. Slide 23: Intermezzo: approved for middle-of-the-night dosing

    Intermezzo: the first and only sleep aid approved for middle-of-the night dosing  Novel and patent-protected zolpidem formulation – Sublingual tablet – Bicarbonate-carbonate buffers  Approved dose – 1.75 mg in women & patients > 65 years – 3.5 mg in men < 65 years  Rapidly absorbed in both men an

  24. Slide 24: Intermezzo: challenges & opportunities

    Intermezzo: challenges & opportunities  Despite Purdue’s promotional effort and investment, INTERMEZZO has yet to achieve sales expectations / potential – For highest prescribers of hypnotics, insomnia is usually not the primary reason that patient is being seen by the physician – Low physician awa

  25. Slide 25: Financial position June 30, 2013

    Financial position June 30, 2013  Cash, equivalents & investments: ~$78MM  Shares outstanding 19 M Options / warrants / other: 4 M Total: 23 M  Employees (FTEs): 12.5 25

  26. Slide 26: Neuroscience focused specialty pharmaceutical company

    Transcept Pharmaceuticals: Neuroscience focused specialty pharmaceutical company 26  First and only product approved for middle of the night insomnia  Marketed in US under partnership with Purdue Pharma INTERMEZZO® for MOTN insomnia  ~$78MM in cash as of 6/30/13; no debt Strong balance sheet  Su

  27. Slide 27: Specialty pharmaceutical company focused on neuroscience

    A specialty pharmaceutical company focused on the development and commercialization of proprietary products to address important therapeutic needs in the field of neuroscience NASDAQ:TSPT September 2013

Transcept Pharmaceuticals — Investor Presentation (September 2013) on 6ix